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A Novel State Funded Program to Increase Cord Blood
Collections for Public Banking
Geralyn Annett. Stem Cell Program, UC Davis Medical Center,
Sacramento, CA
The Umbilical Cord Blood Collection Program (UCBCP),
administered by UC Davis Health System, is a new statewide
public program designed to capture the genetic diversity of
Californians through collection of cord blood units (CBUs) for
unrelated transplantation. This program is funded with
revenue from California state birth certiﬁcate fees. The vision
for the implementation of the mission by UCBCP is to expand
access to cord blood stem cells by targeting current inventory
deﬁciencies to provide greater probabilities that people of
any race or ethnicity will ﬁnd an appropriately matched CBU
in the National Cord Blood Inventory (NCBI). In support of
these goals, the UCBCP plans to promote targeted education
programs for health professionals and to utilize best prac-
tices for cord blood collections. Through this process UCBCP
will facilitate the provision of high quality CBUs for trans-
plantation, as well as promote research and development of
effective treatments utilizing cord blood stem cells by
making the CBUs collected that do not meet the criteria for
banking available to researchers.
Much progress has been made toward developing a sustain-
able cord blood collection program for the state over the ﬁrst
year. The UCBCP leadership team has been developed andwe
have identiﬁed cord blood banks through an RFP bidding
process that will be partnered with hospitals in various parts
of the state. The UCBCP is in varying stages of contract
negotiations with three of the public banks who responded
to the RFP. To date negotiations are in place for California
collections in Southern California to occur at ﬁve Scripps
hospitals, funded in part by the UCBCP; and by collections set
to begin at 13 Kaiser Hospitals, also with support from the
UCBCP. In the Central Valley, a collection site is being
developed in Fresno, at the Community Regional Medical
Center. In the Bay area the UCBCP is in negotiations with
several hospitals, including California Paciﬁc Medical Center
and Alta Bates. In the Sacramento area, the UCBCP has
commitments from 2 hospitals and are seeking the same
from two additional birthing centers. At UCDHS, we have
received IRB approval for the program, and have now initi-
ated cord blood collections for purposes of collector training
and process validation.
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CB is a viable alternative source of allogeneic HSC for the
treatment of malignant and non-malignant disease (Cairo et
al BBMT 2008, Szabolcs/Cairo et al Sem in Hem 2010). NK cells
play a role in innate and adaptive immunity and are char-
acterized as CD56+ cell population. Cytotoxic CD56+dim cells
make up 90% of PB NK populations (Shereck/Cairo PBC 2007).
We previously ex-vivo expanded CB MNC into various
phenotypes of CD56+dim and +bright NK cells (Ayello/Cairo
BBMT 2006; Exp. Hematology 2009). NK cell anti-leukemic
and anti-rejection activities may be essential to the interplay
between GVT effects and GVHD after haploidentical HSCT
(Dunbar et al, Haematologica, 2008).
Objective: To determine differential expression, immuno-
phenotype and genomic and proteomic signatures in CB vs
PB CD56+dimNK cells.
Methods: CB NK CD56 cells (94% enrichment) isolated using
a standardkit (MiltenyiBiotec)andsorted intoCD3-/CD56bright
and CD3-/CD56dim subsets. NKR expression was measured by
ﬂow-cytometry. Isolated RNA from CB and PB CD56+dimcells
underwent microarray studies (Affymetrix, U133A_2).
(Agilent GeneSpring and Ingenuity pathway analyses, IPA).
Proteomic performed by LC MS/MS with iTRAQ labeling and
analyzed with SEQUEST, ProteinProphet, and INTERACT.
Results: There was no difference in NKR expression of CD16,
KIR2DL1, KIR2DS1, KIR2DL2, CD161, NKG2C, NKp44, and
NKp46 in CB vs. PB CD56dim. There was a signiﬁcant differ-
ence in CB vs PB CD56+dim NK cells in gene expression
including: pro-apoptotic genes: CASP10 (3.1F), TNFSF11
(4.7F), CDC2 (3.0F), BCL2L1 (4.3F), NOTCH2 (1.5F); and cell
development: PBX1 (7.6F), IL1RN (5.1F), CD24 (5.3F), CD34
(3.5F), CD55 (2.1F), CCL13 (2.2F). Further, there was a signif-
icant change in protein expression, CB vs PB CD56+dimcells
over 35 proteins, including CELSR1 (25.0F), BLM (25.0F),
BDNF (20.0F), PKD1 (16.7F), NOTCH2 (16.7F), BIRC2 (12.5F),
AIFM1 (12.5F), EP400 (5.3F), PBX1 (3.9F), SIRT2 (2.9F), LETM1
(2.9F), and ESR2 (2.4F). qRT-PCR and Western blot analysis
validated the genomic and proteomic results, respectively.
Conclusion: These results suggest that CB vs PB CD56+dim NK
cells are more prone to undergo programmed cell death
(apoptosis), over expression of numerous pro-apoptotic
genes, and may be earlier in development (pro-NK) with
signiﬁcant over expression of CD34.467
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